Supplemental Table: Hematologic and Nonhematologic TEAEs in the Tal-Only Cohort[a]

TEAEs (≥35%), n (%)	Total Tal-only cohort (N=19)	
	Any Grade	Grade 3/4
Hematologic AEs[b]		
Neutropenia	11 (57.9)	10 (52.6)
Thrombocytopenia	10 (52.6)	6 (31.6)
Anemia	7 (36.8)	3 (15.8)
Nonhematologic AEs		
Skin and subcutaneous tissue disorders[c]	18 (94.7)	0
Infections[d]	12 (63.2)	6 (31.6)
Dysgeusia[e]	12 (63.2)	-
CRS	8 (42.1)	0
Xerostomia	8 (42.1)	0

Per CTCAE v5.0. [a]Includes all patients from the concurrent control group of cohorts B and C. [b]Maximum toxicity grade. [c]Includes dry skin, skin exfoliation, pruritus, onychomadesis, palmar-plantar erythrodysesthesia syndrome, nail dystrophy, erythema, nail disorder, onychoclasis, onycholysis, rash, dermatitis, eczema, exfoliative rash, madarosis, night sweats, palmar erythema, petechiae, photosensitivity reaction, plantar erythema, erythematous rash, maculopapular rash, pruritic rash, and skin fissures. [d]Maximum toxicity grade by System Organ Class. Most common infections were pneumonia (15.8%) and gastroenteritis (10.5%). [e]Maximum grade of dysgeusia is 2 per CTCAE.
AE, adverse event; CRS, cytokine release syndrome; CTCAE, Common Terminology Criteria for Adverse Events; Tal, talquetamab; TEAE, treatment-emergent adverse event.

Supplemental Figure: PRO-CTCAE Severity of Dysgeusia and Dry Mouth in the Tal-Only Cohort[a] Time





[a]Includes all patients from the concurrent control group of cohorts B and C. [b]Patients responded to the prompt "In the last 7 days, what was the severity of your problems with tasting food or drink at their worst?"
BL, baseline; C, cycle; D, day; PRO-CTCAE, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events; Tal, talquetamab.